Search

Displaying results 3381 - 3390 of 10000 in total
  1. Drug

    Yohimbine

    go.drugbank.com/drugs/DB01392
    ApprovedInvestigationalVet approvedWithdrawn

    A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.

    Categories: Heterocyclic Compounds, 2-Ring, Adrenergic alpha-2 Receptor AntagonistsSynonyms: (16α,17α)-17-hydroxyyohimban-16-carboxylic acid methyl ester
  2. Drug

    Terfenadine

    go.drugbank.com/drugs/DB00342
    ApprovedWithdrawn

    In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.

    Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein inhibitorsSynonyms: (RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol
  3. Drug

    Dimercaptosuccinic acid

    go.drugbank.com/drugs/DB14089
    ApprovedInvestigational

    Categories: Compounds used in a research, industrial, or household settingProducts: MON.DMSA KIT 1 MG IV ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON, 5 ADET
  4. Drug

    Vindesine

    go.drugbank.com/drugs/DB00309
    ApprovedInvestigationalWithdrawn

    Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 3-carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
  5. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.

    Products: EMPAVELI® 54 MG/ML SOLUCIÓN INYECTABLE
  6. Drug

    Flumethasone

    go.drugbank.com/drugs/DB00663
    ApprovedVet approved

    As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. … This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.

    Mixtures: LOCACORTENE VİOFORME 0,2 MG/G+30 MG/G KREM, 15 G, LOCACORTENE VİOFORME 0,2 MG/G+30 MG/G KREM, 30 GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Remlarsen

    go.drugbank.com/drugs/DB19131
    Investigational

    Remlarsen is under investigation in clinical trial NCT03601052 (Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids).

    Synonyms: -cholest-5-en-3-yloxy)hexyl)oxy)-2-hydroxypropyl hydrogen phosphate), complex with rna ((2'-deoxy-2'-fluoro)u-a-g-(2'-deoxy-2'-fluoro)c-a-(2'-deoxy-2'-fluoro)c-(2'-de, Rna, (am-am-cm-a-cm-um-g-um-um-um-a-cm-a-a-a-um-g-g-um-cm-cm-um-a), 3'-(3-((6-((3.beta.)
  8. Drug

    Aluminum acetate

    go.drugbank.com/drugs/DB14518
    ApprovedInvestigational

    Mixtures: ZISUAL-C, SPERTI PREPARATION HProducts: ACETATO DE ALUMINIO 15 MG/100 ML SOLUCION TOPICA, ACETATO DE ALUMINIO 0.118G/100 ML
  9. Drug

    Pergolide

    go.drugbank.com/drugs/DB01186
    ApprovedVet approvedWithdrawn

    It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. … Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease.

    Categories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor AgonistsProducts: PERGOLID-NEURAX 1 MG, PERGOLIDE EG
  10. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: ANAGRELID RATIO 1 MG, Anagrelid Nordic 1 mg Tabletten